DNMT3A mutation is a poor prognosis biomarker in AML: Results of a meta-analysis of 4500 AML patients

Leukemia Research

Volumn 37, Issue 11, 2013, Pages 1445-1450

  Shivarov, Velizar ^a   Gueorguieva, Ralitza ^b   Stoimenov, Angel ^a   Tiu, Ramon ^c  

^a National Hematology Hospital   (Bulgaria)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c LERNER RESEARCH INSTITUTE   (United States)

Author keywords

AML; DNMT3A mutations; Meta analysis; Prognosis

Indexed keywords

BIOLOGICAL MARKER; CD135 ANTIGEN; DNA METHYLTRANSFERASE 3A; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; DISEASE MARKER; DNMT3A GENE; GENE MUTATION; GENETIC ASSOCIATION; GENOTYPE; HIGH RISK PATIENT; HUMAN; OVERALL SURVIVAL; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL;

AML; DNMT3A MUTATIONS; META-ANALYSIS; PROGNOSIS;

DNA (CYTOSINE-5-)-METHYLTRANSFERASE; HUMANS; LEUKEMIA, MYELOID, ACUTE; MUTATION; PROGNOSIS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886804684     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.07.032     Document Type: Article

References (22)

1. Marcucci G., Haferlach T., Dohner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol 2011, 29(5):475-486.
2. Sanders M.A., Valk P.J. The evolving molecular genetic landscape in acute myeloid leukaemia. Curr Opin Hematol 2013, 20(2):79-85.
3. Dohner H., Estey E.H., Amadori S., et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood 2010, 115(3):453-474.
4. Patel J.P., Gonen M., Figueroa M.E., et al. Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. N Engl J Med 2012, 366(12):1079-1089.
5. Yamashita Y., Yuan J., Suetake I., et al. Array-based genomic resequencing of human leukemia. Oncogene 2010, 29(25):3723-3731.
6. Ley T.J., Ding L., Walter M.J., et al. DNMT3A mutations in acute myeloid leukemia. N Engl J Med 2010, 363(25):2424-2433.
7. Yan X.J., Xu J., Gu Z.H., et al. Exome sequencing identifies somatic mutations of DNA methyltransferase gene DNMT3A in acute monocytic leukemia. Nat Genet 2011, 43(4):309-315.
8. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99(3):247-257.
9. Thol F., Damm F., Ludeking A., et al. Incidence and prognostic influence of DNMT3A mutations in acute myeloid leukemia. J Clin Oncol 2011, 29(21):2889-2896.
10. Hozo S.P., Djulbegovic B., Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 2005, 5:13.
11. Tierney J.F., Stewart L.A., Ghersi D., Burdett S., Sydes M.R. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007, 8:16.
12. Parmar M.K., Torri V., Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 1998, 17(24):2815-2834.
13. Hou H.A., Kuo Y.Y., Liu C.Y., et al. DNMT3A mutations in acute myeloid leukemia: stability during disease evolution and clinical implications. Blood 2012, 119(2):559-568.
14. Renneville A., Boissel N., Nibourel O., et al. Prognostic significance of DNA methyltransferase 3A mutations in cytogenetically normal acute myeloid leukemia: a study by the Acute Leukemia French Association. Leukemia 2012, 26(6):1247-1254.
15. Ribeiro A.F., Pratcorona M., Erpelinck-Verschueren C., et al. Mutant DNMT3A: a marker of poor prognosis in acute myeloid leukemia. Blood 2012, 119(24):5824-5831.
16. Ostronoff F., Othus M., Ho P.A., et al. Mutations in the DNMT3A exon 23 independently predict poor outcome in older patients with acute myeloid leukemia: a SWOG report. Leukemia 2013, 27(1):238-241.
17. Marcucci G., Metzeler K.H., Schwind S., et al. Age-related prognostic impact of different types of DNMT3A mutations in adults with primary cytogenetically normal acute myeloid leukemia. J Clin Oncol 2012, 30(7):742-750.
18. Gaidzik V.I., Schlenk R.F., Paschka P., et al. Clinical impact of DNMT3A mutations in younger adult patients with acute myeloid leukemia: results of the AML Study Group (AMLSG). Blood 2013, 121(23):4769-4777.
19. Wakita S., Yamaguchi H., Omori I., et al. Mutations of the epigenetics-modifying gene (DNMT3a, TET2, IDH1/2) at diagnosis may induce FLT3-ITD at relapse in de novo acute myeloid leukemia. Leukemia 2013, 27(5):1044-1052.
20. Markova J., Michkova P., Burckova K., et al. Prognostic impact of DNMT3A mutations in patients with intermediate cytogenetic risk profile acute myeloid leukemia. Eur J Haematol 2012, 88(2):128-135.
21. LaRochelle O., Bertoli S., Vergez F., et al. Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. Oncotarget 2011, 2(11):850-861.
22. Metzeler K.H., Walker A., Geyer S., et al. DNMT3A mutations and response to the hypomethylating agent decitabine in acute myeloid leukemia. Leukemia 2012, 26(5):1106-1107.